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PRIMARY PLERIXAFOR MOBILIZATION IN AUTOLOGOUS HEMATOPOI-
ETIC CELL TRANSPLANT CANDIDATES AT HIGH RISK FOR MOBILIZATION
FAILURE
Shapiro, J., Bookout, R., Perkins, J., Ayala, E., Alsina, M., Field, T.,
Kharfan-Dadaja, M.A., Perez, L.E., Ochoa-Bayona, J.L.,
Tomblyn, M., LaFave, D., Anasetti, C., Fernandez, H.F. Moffitt Cancer
Center, Tampa, FL
Plerixafor has recently become commercially available for use as
a mobilizing agent in patients undergoing CD34+ hematopoietic
cell collection in preparation for autologous transplantation. Prac-
tice guidelines were developed to optimize the use of plerixafor at
our institution. Within those guidelines, we defined patients at
high risk for mobilization failure as those who met the following cri-
teria: 1) Received 3 lines of prior chemotherapy; 2) Received 2 lines
of prior chemotherapy plus a radioimmunoconjugate 3) Received 2
lines of prior chemotherapy plus radiation therapy to extensive fields;
4) Received 4 or more cycles of hyper-CVAD or more than 4 cycles
of lenalidomide; 5) Hypocellular marrow (\25% cellularity); 6)
Platelet count\100,000/mL
We report here preliminary data on 19 consecutive high-risk pa-
tients who have received plerixafor as primary mobilization therapy.
The median age of the patients was 60 (range 33-71) years. Diagno-
ses include multiple myeloma (12), non-Hodgkin’s lymphoma (6)
and Hodgkin’s disease (1). Patients received a median of 2 (range
1-5) lines of prior chemotherapy and 6 patients also received prior
radiation therapy. All patients received 4 doses of G-CSF (10 mcg/
kg/d) and on the evening of the forth dose, they also received plerix-
afor 0.24 mg/kg except for 3 patients who were dosed at 0.16 mg/kg
due to reduced creatinine clearance. Apheresis was started the morn-
ing after the first dose of plerixafor. G-CSF, plerixafor, and apheresis
were continued until at least 2 106 CD34+ cells/kg were collected.
The median number (range) of G-CSF doses, plerixafor doses and
aphereses were 4 (4-7), 1 (1-3), and 1 (1-3), respectively. The number
of patients collecting at least 2 106 CD34+ cells (cumulative) on 1,
2, and 3 aphereses were 15 (79%), 17 (89%), and 19 (100%). Theme-
dian (range) of the total number of CD34+ cells/kg collected for all
patients was 4.99 (2.07-23.65)x 106. All patients have been trans-
planted. Eighteen patients are evaluable for neutrophil recovery; me-
dian time to absolute neutrophil count. 500/mL was 12 (range 10-
12) days. Fourteen patients have recovered platelet counts. 20,000/
mL (without transfusion for 7 days) at median of 18 days (range 14-
42) post-transplant. We conclude that plerixafor is beneficial in
patients who are at high risk formobilization failurewith 100%of pa-
tients mobilizing adequate CD34+ cells counts in 3 aphereses or less.Table 1. Characteristics of the patients included in the vali-
dation cohort
Characteristic Number of patients Percentage
Diagnosis
Multiple Myeloma 23 82
Lymphoma 5 18
Age
#60 17 61
.60 11 39
Gender
Male 10 36
Female 18 64
Prior radiation 10 36
Prior lines of therapy- Lymphomas
#2 5 100
.2 0 0
Prior lines of therapy- Myeloma
#1 10 43
.1 13 57
Prior lenalidomide 14 61
Target CD341/kg for mobilization
3x10e6 13 46
6x10e6 15 54132
AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
WITH INDUCTION OF AUTOLOGOUS GRAFT-VERSUS-HOST DISEASE IN
ACUTE MYELOID LEUKEMIA – LONG-TERM F/U DATA
Park, J.1, Park, S.H.2, Kim, S.Y.3, Ko, Y.4, Kim, K.2, Jung, C.W.2,
Lee, J.H.1, Lee, H.M.3 1Gachon University of Medicine and Science,
Gil Medical Center, Incheon, Korea; 2Samsung Medical Center, Sung-
kyunkwan University School of Medicine, Seoul, Korea; 3Konkuk Univer-
sity Hospital, Konkuk University School of Medicine, Seoul, Korea;
4SamsungMedical Center, SungkyunkwanUniversity School ofMedicine,
Seoul, Korea
We previously published data that suggested that induction of an
autologous graft-versus-host disease (GVHD) has an anti-leukemic
effect, consequently increasing the survival rate of patients who un-
dergo autologous peripheral blood stem cell transplantation
(PBSCT). Here we report the long term follow up data regarding
the overall survival (OS) and disease free survival (DFS). In total,
22 acute myeloid leukemia patients with favorable and intermediate
cytogenetic risk, in their first complete remission, were administered
cyclosporine c.i.v. from day 0 to day +28 at a dose of 3.0 mg/kg per
day and interferon- g (IFN- g) at 0.025 mg//m2 s.c. every other day
from day +14 to day +42 following autologous PBSCT. Natural-
killer (NK) – cell activity assays and skin biopsies were performed.
Engraftment was successful in all patients at a median of 13 days
without any significant additional toxicity. Histologically confirmed
that cutaneous GVHD had developed in 12 patients, and NK-cellactivity was significantly augmented after the autologous PBSCT
in those patients (P5 0.03). After a median follow-up duration of
117.6 months (range, 87.3-152.8), the 3-year DFS and OS rates
were 68.2% and 72.7%, respectively, and the 5-year DFS and OS
rates were 63.6% and 73%, respectively. They were without signif-
icant correlation with GVHD status or augmentation of NK-cell ac-
tivity. The median OS was unreached yet.
This data suggests that the administration of cyclosporine and
IFN-g following autologous PBSCT improves OS and DFS, which
may be attributable to the antileukemic effect, although no differ-
ence in survival rates could be demonstrated between cutaneous
GVHD-positive and -negative groups.133
VALIDATION OF A DECISION-MAKING ALGORITHM TO GUIDE THE USE
OF PLERIXAFOR FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBI-
LIZATION
Costa, L.J., Alexander, E., Hogan, K.R., Fouts, T.V., Kramer, C.,
Schaub, C., Stuart, R.K. Medical University of South Carolina, Charles-
ton, SC
Background: Plerixafor, an inhibitor of CXCR-4/SDF-1 binding, is
approved for mobilization of peripheral blood hematopoietic stem
cells (PBHSC) prior to autologous hematopoietic stem cells trans-
plantation (AHSCT) for non-Hodgkin lymphomas and multiple
myeloma (MM). We developed a cost-saving decision making algo-
rithm that utilizes the CD34+ count in the peripheral blood on the
4th day of G-CSF administration (PB-CD34+) and the target
CD34+ count for the specific patient (T-CD34+) to decide between
starting collection on day 4 and continuing G-CSF administration
only (G approach) or adding Plerixafor the night before each apher-
esis session and starting apheresis on day 5 (G + P approach). The al-
gorithm was based on actual mobilization data and analysis of
mobilization charges aiming at finding the approach likely to have
the lowest charge for each circumstance. The development of this al-
gorithm has been previously presented (ASH 2009, abstract 3216)
Methods: We reviewed mobilization and collection data on 28 pa-
tients who have completed mobilization on the MUSCmobilization
algorithm. Additionally, we reviewed engraftment data for the 19 pa-
tients who have undergone a first autologous transplantation.
Results: Twenty eight patients have been included in the validation
cohort. Patient characteristics are displayed in table 1. Nine patients
(33%) completed collections with theG approach and 19 (68%) with
the G + P approach. There were no collection failures. Twenty-six
